Revolution Medicines readies IPO

Revolution Medicines (RVMD) has filed a preliminary prospectus for a $100M IPO.

The Redwood City, CA-based biotech develops cancer therapies that, it says, inhibit elusive, high-value frontier targets with notorious growth and survival pathways such as RAS and mTOR. Lead candidate is RMC-4630, an SHP2 inhibitor, in Phase 1/2 development with collaboration partner Sanofi.

2019 Financials (9 mo.): Collaboration Revenue: $38.0M (+288%); Operating Expenses: $72.5M (+88%); Net Loss: ($43.1M) (-23%); Cash Consumption: ($38.0) (-292%).


Leave a Reply